• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa

Analyst Comment 30.06.2026, 07.55 by Antti Siltanen
Orion

Biohit: Sold on summer sale

Research 29.06.2026, 08.00 by Antti Siltanen
Biohit

Herantis appointed a Chief Medical Officer

Analyst Comment 26.06.2026, 07.51 by Antti Siltanen
Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Aiforia collects 6.4 MEUR in a directed share issue

Analyst Comment 26.06.2026, 07.49 by Antti Siltanen
Aiforia Technologies

Bioretec Extensive Report: Signs of recovery in growth fracture

Extensive research 25.06.2026, 13.13 by Antti Siltanen
Bioretec

Orions ODM-212 fik også særstatus som lægemiddel i EU

Analyst Comment 24.06.2026, 06.00 by Antti Siltanen
Orion

Bioretec concluded change negotiations for production

Analyst Comment 18.06.2026, 07.45 by Antti Siltanen
Bioretec

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

Analyst Comment 16.06.2026, 08.16 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Faron's BEXMAB update provided additional information on response duration

Analyst Comment 16.06.2026, 08.15 by Antti Siltanen
Faron Pharmaceuticals

Significant one-time order for Nexstim

Analyst Comment 12.06.2026, 08.28 by Antti Siltanen
Nexstim